Navigation Links
Secretropin(R) - Effective, Preferable, Affordable as an Alternative to Injectable Growth Hormone - Gains Momentum
Date:2/2/2009

ENCINO, Calif., Feb. 2 /PRNewswire/ -- Secretropin(R), the first clinically proven natural stimulator of growth hormone production, is gaining the medical community's acceptance as a more desirable "first step" approach to pursuing hormonal balance. Although classified as a natural food supplement, Secretropin(R) is only available through a prescribing physician due to its clinically proven ability to increase the body's own production and release of growth hormone. This reproducible response of Secretropin's(R) use is reflected in its recently posted 9-month retail sales record of $1M.

Developed in 2001, Secretropin(R) received early medical acknowledgement for 2 key reasons: one, its reproducible effectiveness; and two, its preferable oral delivery. In as little as 4 weeks Secretropin(R) has been shown to increase the production of growth hormone by 50 - 200% while being delivered as an oral spray. Secretropin's(R) oral delivery system (ODS) owes its effectiveness to the latest nanoliposomal technology, which wraps the active agents in a protective envelop. Until this delivery technology was available, stomach acid would inactivate and destroy the active agents responsible for the increase in growth hormone production.

Prior to Secretropin(R), this left injectable growth hormone as the only other viable option. Fortunately, the nanoliposomal technology protects the complex, allowing for optimal absorption and leading to a more natural increase in growth hormone levels - thus eliminating the less desirable approach of daily injections.

On the financial side, the present global market for injectable human growth hormone (HGH) therapy is estimated to exceed $3B. The market is growing at a projected 15 to 20% rate as the world medical community recognizes the benefits to maintaining healthy hormone levels throughout life. Currently, injectable GH therapy costs approximately $1000/month, and with the technological advances captured by Secretropin(R), the cost range has been significantly reduced to between $150 and $200/month.

The Millennium Health Center, Inc. participated in the development of Secretropin(R) and provides ongoing clinical research (report). As of October 2006, there are over 3000 patient months of data being compiled by a number of independent centers throughout the U.S., Australia, New Zealand, India, Russia, Thailand, China, and Dubai. So far, Secretropin's(R) ability to increase growth hormone production has been reported in excess of 95% of the cases.

The combination of known benefits of healthy levels of human growth hormone, plus Secretropin's(R) clinically documented response rate, added to its cost-effectiveness, is what is being labeled as a responsible first-step approach to pursuing age-appropriate hormonal balanced therapy.

    For additional information:

    Mark L. Gordon, M.D.
    Millennium Health Centers, Inc.
    Email: Info@secretropinrx.com

Website: http://www.secretropinrx.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Millennium Health Centers, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
2. ZhenSpa.com provides Spa Enthusiasts Affordable Alternatives for Expensive Spa Treatments
3. DNA 11, Creators of DNA Art, Introduces a More Affordable Line of Custom Portraits for this Year's Gift Giving Season
4. BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices
5. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
6. XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
7. XTENT to Retain Investment Bank to Pursue Strategic Alternatives
8. N-Viro Fuel Technology Receives Alternative Energy Status From the U.S. Environmental Protection Agency
9. New uses for imidazolium salts in medicine and alternative energy
10. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
11. CPC of America, Inc. to Explore Strategic Alternatives; Appoints FTI Capital Advisors to Assess Potential Opportunities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 5, 2016 Australian-US drug discovery and development company, ... appointment of a new Chairman, Mr John O,Connor , ... immediately. James Garner , has also been ... former Acting CEO, Mr Iain Ross , will resume ... --> James Garner , has also been formally appointed ...
(Date:2/4/2016)... , February 4, 2016 - New FDA action ... - New FDA action date of July 22, ... July 22, 2016   - ... in the past decade indicated for the treatment of signs and symptoms of ... has the potential to be the only product approved in the U.S. in ...
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific Instruments ... host live demos and poster sessions, and present on the analysis of mycotoxins ... place March 6 to 10 at the Georgia World Congress Center in Atlanta, ...
(Date:2/4/2016)... -- Beike Biotechnology, the Shenzhen ... in late 2015 to mark their successful combined efforts ... --> --> The signing, ... Therapy" was hosted by the Shenzhen Cell Bank and ... Beike Biotechnology Co., Ltd. Shenzhen,s ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 3, 2016 ... market research report "Automated Fingerprint Identification System Market by ... Search), Application (Banking & Finance, Government, Healthcare, and Transportation) ... MarketsandMarkets, the market is expected to be worth USD ... 21.0% between 2015 and 2020. The transformation and technology ...
(Date:2/2/2016)... 2, 2016  BioMEMS devices deployed in ... on medical screening and diagnostic applications, such ... devices that facilitate and assure continuous monitoring ... are being bolstered through new opportunities offered ... acquisition coupled with wireless connectivity and low ...
(Date:2/2/2016)... Technology Enhancements Accelerate Growth of X-ray Imaging ... and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth analysis ... as regional market drivers and restraints. The study offers ... market attractiveness, both for digital and computed radiography. Market ...
Breaking Biology News(10 mins):